Investors

Presentation at Aktiespararna: Neola Medical’s progress, plans and rights issue presented by CEO

June 11, 2026

At Aktiespararna’s Aktiedagarna in Stockholm, Neola Medical’s CEO Hanna Sjöström presented the company’s recent clinical progress, future plans and ongoing rights issue to a live audience. The presentation highlighted how the rights issue is intended to support the company’s continued journey toward FDA approval and market launch.
 
Watch the full presentation here:
https://www.youtube.com/watch?v=vuAi2JblyJk
 
Read additional insights from Nyemissioner.se here:
https://nyemissioner.se/nyheter/neola-medical-tar-sikte-pa-usa-efter-lyckad-klinisk-studie

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Presentation at Aktiespararna: Neola Medical’s progress, plans and rights issue presented by CEO